Search research articles
Contact Us
Filters
Showing results (91-100 of 105) with videos related to
Page
of 11
Sort By:
Gynecologic Oncology
|
May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Joyce F Liu, Niya Xiong, Robert M Wenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 29, 2019
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
Panagiotis A Konstantinopoulos, Weixiu Luo, Joyce F Liu, et al.
British Journal of Cancer
|
December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.
NPJ Precision Oncology
|
May 30, 2026
Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer
Doris Kim, Heekyung Chung, Mona Abed, et al.
Cancer Discovery
|
September 15, 2018
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Sarah J Hill, Brennan Decker, Emma A Roberts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2016
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Joyce F Liu, Sangeetha Palakurthi, Qing Zeng, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
May 12, 2018
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)
Helena M Ditzel, Kyle C Strickland, Emily E Meserve, et al.
Gynecologic Oncology
|
May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer
Elizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
Cancer Research
|
October 15, 2024
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors
Louise Cadzow, Jehrod Brenneman, Erica Tobin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2017
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Douglass W Tucker, Christopher R Getchell, Eric T McCarthy, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 105) with videos related to
Sort By:
Page
of 11
Gynecologic Oncology
|
May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Joyce F Liu, Niya Xiong, Robert M Wenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 29, 2019
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
Panagiotis A Konstantinopoulos, Weixiu Luo, Joyce F Liu, et al.
British Journal of Cancer
|
December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.
NPJ Precision Oncology
|
May 30, 2026
Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer
Doris Kim, Heekyung Chung, Mona Abed, et al.
Cancer Discovery
|
September 15, 2018
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Sarah J Hill, Brennan Decker, Emma A Roberts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2016
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Joyce F Liu, Sangeetha Palakurthi, Qing Zeng, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
May 12, 2018
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)
Helena M Ditzel, Kyle C Strickland, Emily E Meserve, et al.
Gynecologic Oncology
|
May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer
Elizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
Cancer Research
|
October 15, 2024
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors
Louise Cadzow, Jehrod Brenneman, Erica Tobin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2017
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Douglass W Tucker, Christopher R Getchell, Eric T McCarthy, et al.
Page
of 11